Bio Medica Laboratories Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹-7(-5.04%)
Premium (ELP)
Having completed its public offering, Bio Medica Laboratories Limited's is now listed and trading on the NSE exchange as of May 29, 2026. The IPO raised cumulative capital of 37,72,000 Shares, including 33,95,000 Shares in primary capital infusion and ₹5.24 Cr in secondary market transactions.
The IPO was conducted with a price range of ₹132 to ₹139 and minimum investment requirement of 1000 shares. subscription activity between May 21, 2026 and May 25, 2026 reflected market assessment of the offering's valuation and prospects.
The allotment process finalized on May 26, 2026 distributed equity ownership to successful bidders. The listing established a transparent market mechanism for share trading, price discovery, and investor participation in the company's future growth.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Bio Medica Laboratories is a pharmaceutical company engaged in manufacturing parenteral formulations for both human and veterinary healthcare segments. The company produces a wide range of ethical drugs, generic medicines, and OTC products, primarily in liquid and dry powder injectable forms. Its portfolio includes 58 liquid injectables and 15 dry powder injectable products available in single-dose and multi-dose formats. Operating on a B2B contract manufacturing model, the company develops customized formulations according to client requirements. Supported by GMP and GLP certifications, Bio Medica runs two manufacturing facilities in Indore, Madhya Pradesh, focusing on quality production and pharmaceutical formulation development.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Diversified Injectable Portfolio: Offers a wide range of liquid and dry powder injectables for various therapeutic needs.
- Strong Contract Manufacturing: B2B-focused model supports customized formulation development for pharmaceutical clients.
- Experienced Management & Workforce: Industry-experienced teams support efficient manufacturing and quality standards.
- Regulatory Compliance Risk: Previous suspension of operations at a manufacturing unit due to non-compliance may affect reputation and business operations.
- Customer Concentration Risk: Dependence on a limited number of clients may impact financial performance if key customers are lost.
- Quality Control & Manufacturing Risk: Product defects or quality issues may lead to litigation, regulatory action, and reputational damage.
- Mr. Mukesh Mehta
- Mr. Pradeep Mehta
Bio Medica Laboratories Limited
Skyline Financial Services Private Limited